[HTML][HTML] Identification of favorable subgroups for alternative anti‑androgen therapy in castration‑resistant prostate cancer
K Suzuki, T Terakawa… - Molecular and …, 2019 - spandidos-publications.com
Although alternative anti‑androgen therapy (switching to secondary anti‑androgens) is no
longer recommended in the clinical guidelines of prostate cancer in light of the new …
longer recommended in the clinical guidelines of prostate cancer in light of the new …
Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer
K Suzuki, T Terakawa, K Shigemura… - Molecular and …, 2019 - search.proquest.com
Although alternative anti-androgen therapy (switching to secondary anti-androgens) is no
longer recommended in the clinical guidelines of prostate cancer in light of the new …
longer recommended in the clinical guidelines of prostate cancer in light of the new …
Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer.
K Suzuki, T Terakawa, K Shigemura… - Molecular & Clinical …, 2019 - search.ebscohost.com
Although alternative anti-androgen therapy (switching to secondary anti-androgens) is no
longer recommended in the clinical guidelines of prostate cancer in light of the new …
longer recommended in the clinical guidelines of prostate cancer in light of the new …
Identification of favorable subgroups for alternative anti‑androgen therapy in castration‑resistant prostate cancer
K Suzuki, T Terakawa, K Shigemura… - Molecular and …, 2019 - da.lib.kobe-u.ac.jp
Although alternative anti-androgen therapy (switching to secondary anti-androgens) is no
longer recommended in the clinical guidelines of prostate cancer in light of the new …
longer recommended in the clinical guidelines of prostate cancer in light of the new …
Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer
K Suzuki, T Terakawa, K Shigemura… - Molecular and …, 2019 - pubmed.ncbi.nlm.nih.gov
Although alternative anti-androgen therapy (switching to secondary anti-androgens) is no
longer recommended in the clinical guidelines of prostate cancer in light of the new …
longer recommended in the clinical guidelines of prostate cancer in light of the new …
[PDF][PDF] Identification of favorable subgroups for alternative anti‑androgen therapy in castration‑resistant prostate cancer
K SUZUKI, T TERAKAWA, K SHIGEMURA… - MOLECULAR AND …, 2019 - researchgate.net
Although alternative anti-androgen therapy (switching to secondary anti-androgens) is no
longer recommended in the clinical guidelines of prostate cancer in light of the new …
longer recommended in the clinical guidelines of prostate cancer in light of the new …
Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer.
K Suzuki, T Terakawa, K Shigemura… - Molecular and Clinical …, 2019 - go.gale.com
Androgen deprivation therapy (ADT) is the standard treatment for patients with newly
diagnosed metastatic prostate cancer and for those with recurrent prostate cancer after …
diagnosed metastatic prostate cancer and for those with recurrent prostate cancer after …
Identification of favorable subgroups for alternative anti‑androgen therapy in castration‑resistant prostate cancer
K SUZUKI, T TERAKAWA… - MOLECULAR AND …, 2019 - ingentaconnect.com
Although alternative antiandrogen therapy (switching to secondary antiandrogens) is no
longer recommended in the clinical guidelines of prostate cancer in light of the new …
longer recommended in the clinical guidelines of prostate cancer in light of the new …
[HTML][HTML] Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer
K Suzuki, T Terakawa, K Shigemura… - … and Clinical Oncology, 2019 - ncbi.nlm.nih.gov
Although alternative anti-androgen therapy (switching to secondary anti-androgens) is no
longer recommended in the clinical guidelines of prostate cancer in light of the new …
longer recommended in the clinical guidelines of prostate cancer in light of the new …
Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer.
K Suzuki, T Terakawa, K Shigemura… - … and Clinical Oncology, 2019 - europepmc.org
Although alternative anti-androgen therapy (switching to secondary anti-androgens) is no
longer recommended in the clinical guidelines of prostate cancer in light of the new …
longer recommended in the clinical guidelines of prostate cancer in light of the new …